The art of the deal? Why a money-back guarantee for drugs is a bad idea
President Trump likes to boast that he mastered the “art of the deal.” But one option his administration is considering to encourage lower drug prices, which surfaced in a recent draft executive order, may not be much of a deal for consumers

The art of the deal? Why a money-back guarantee for drugs is a bad idea

President Trump likes to boast that he mastered the “art of the deal.”

But one option his administration is considering to encourage lower drug prices, which surfaced in a recent draft executive order, may not be much of a deal for consumers.

advertisement

The concept has a clunky name — value-based pricing — but it’s fairly simple. One increasingly popular version works like this: A drug maker refunds some money to an insurer if its medicine fails to improve patient health or prevent a costly incident, such as a heart attack.